Luis A Brito
Overview
Explore the profile of Luis A Brito including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
2424
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bahl K, Senn J, Yuzhakov O, Bulychev A, Brito L, Hassett K, et al.
Mol Ther
. 2022 Aug;
30(8):2874.
PMID: 35921837
No abstract available.
2.
Hassett K, Higgins J, Woods A, Levy B, Xia Y, Hsiao C, et al.
J Control Release
. 2021 May;
335:237-246.
PMID: 34019945
Lipid nanoparticles (LNP) are effective delivery vehicles for messenger RNA (mRNA) and have shown promise for vaccine applications. Yet there are no published reports detailing how LNP biophysical properties can...
3.
Gebre M, Brito L, Tostanoski L, Edwards D, Carfi A, Barouch D
Cell
. 2021 Mar;
184(6):1589-1603.
PMID: 33740454
Vaccines are critical tools for maintaining global health. Traditional vaccine technologies have been used across a wide range of bacterial and viral pathogens, yet there are a number of examples...
4.
Shah R, Taccone M, Monaci E, Brito L, Bonci A, OHagan D, et al.
Sci Rep
. 2019 Aug;
9(1):11520.
PMID: 31395915
Self-emulsification is routinely used for oral delivery of lipophilic drugs in vivo, with the emulsion forming in vivo. We modified this technique to prepare novel oil-in-water emulsions of varying droplet...
5.
Lindgren G, Ols S, Liang F, Thompson E, Lin A, Hellgren F, et al.
Front Immunol
. 2019 Apr;
10:614.
PMID: 31001251
[This corrects the article DOI: 10.3389/fimmu.2017.01539.].
6.
Hassett K, Benenato K, Jacquinet E, Lee A, Woods A, Yuzhakov O, et al.
Mol Ther Nucleic Acids
. 2019 Feb;
15:1-11.
PMID: 30785039
mRNA vaccines have the potential to tackle many unmet medical needs that are unable to be addressed with conventional vaccine technologies. A potent and well-tolerated delivery technology is integral to...
7.
Lodaya R, Brito L, Wu T, Miller A, Otten G, Singh M, et al.
J Pharm Sci
. 2018 Jun;
107(9):2310-2314.
PMID: 29883663
Adjuvants are required to enhance immune responses to typically poorly immunogenic recombinant antigens. Toll-like receptor agonists (TLRa) have been widely evaluated as adjuvants because they activate the innate immune system....
8.
Lindgren G, Ols S, Liang F, Thompson E, Lin A, Hellgren F, et al.
Front Immunol
. 2017 Nov;
8:1539.
PMID: 29181005
Modified mRNA vaccines have developed into an effective and well-tolerated vaccine platform that offers scalable and precise antigen production. Nevertheless, the immunological events leading to strong antibody responses elicited by...
9.
Liang F, Lindgren G, Lin A, Thompson E, Ols S, Rohss J, et al.
Mol Ther
. 2017 Sep;
25(12):2635-2647.
PMID: 28958578
mRNA vaccines are rapidly emerging as a powerful platform for infectious diseases because they are well tolerated, immunogenic, and scalable and are built on precise but adaptable antigen design. We...
10.
Bahl K, Senn J, Yuzhakov O, Bulychev A, Brito L, Hassett K, et al.
Mol Ther
. 2017 May;
25(6):1316-1327.
PMID: 28457665
Recently, the World Health Organization confirmed 120 new human cases of avian H7N9 influenza in China resulting in 37 deaths, highlighting the concern for a potential pandemic and the need...